<?xml version="1.0"?>
<rss version="2.0">
<channel>
<title>GolfStakes.com : Community Forum - Announcements - CAS 52232-67-4 Teriparatide Acetate Peptide - Messages</title>
<link>http://golfstakes.com/forum/messages.aspx?TopicID=20578</link>
<description>GolfStakes.com : Community Forum - Announcements - CAS 52232-67-4 Teriparatide Acetate Peptide - Messages</description>
<language>en-us</language>
<docs>http://blogs.law.harvard.edu/tech/rss</docs>
<generator>Jitbit AspNetForum</generator>
<pubDate>Sat, 05 Oct 2019 09:57:46 GMT</pubDate>
<lastBuildDate>Sat, 05 Oct 2019 09:57:46 GMT</lastBuildDate>
<item>
<link>http://golfstakes.com/forum/messages.aspx?TopicID=20578</link>
<title>Message from goon2019</title>
<description><![CDATA[CAS 52232-67-4 Teriparatide Acetate Peptide<br/><br/><br/><br/><A href="https://www.phcoker.com/product/99294-94-7/" target="_blank" rel="nofollow">Teriparatide Acetate powder</a> is a recombinant form of parathyroid hormone. It is an effective anabolic (i.e., bone growing) agent[1] used in the treatment of some forms of osteoporosis.It is also occasionally used off-label to speed fracture healing. Teriparatide is identical to a portion of human parathyroid hormone (PTH) and intermittent use activates osteoblasts more than osteoclasts, which leads to an overall increase in bone.<br/> Teriparatide is indicated for use in postmenopausal women with osteoporosis at a high risk for fracture or with a history of ostoporotic fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.<br/>Teriparatide is also indicated to increase bone mass in men with primary or hypogonadal osteoporosis at high risk of fracture, patients with multiple risk factors for fracture, and for patients who have failed or are intolerant to other available osteoporosis therapy.<br/>Teriparatide is indicated as well for the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy.<br/>Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget's Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.]]></description>
<pubDate>Sat, 05 Oct 2019 09:57:46 GMT</pubDate>
</item>
</channel>
</rss>
